Cold Pills & Compartmental Modeling Ronnie Schumann MA 354- Math Modeling Dr. Jyoti Champanerkar Monday, Dec. 5, 2005.

Slides:



Advertisements
Similar presentations
Karunya Kandimalla, Ph.D
Advertisements

PHARMACOKINETIC MODELS
PHARMACOKINETIC.
Human Body Drug Simulation Nathan Liles Benjamin Munda.
Other PD Models linked to the basic PK Model Modeling Diffusion into Porous Spherical Objects: Endocardial Vegetations, and the Post-Antibiotic Effect.
Michaelis-Menton Meets the Market. Group Members Jeff Awe Jacob Dettinger John Moe Kyle Schlosser.
Dose-Response Relationships Lesson 6. Dose & Drug Effects n Pharmacodynamics l what the drug does to the body n Effects of drug depends on dose n In general...
Pharmacotherapy in the Elderly Paola S. Timiras May, 2007.
Pharmacotherapy in the Elderly Judy Wong
Pharmacokinetics of Drug Absorption
Modeling in the Time Domain - State-Space
Two-compartment model
Computational Biology, Part 18 Compartmental Analysis Robert F. Murphy Copyright  1996, All rights reserved.
One-compartment open model: Intravenous bolus administration
Week 5- Pharmacokinetics of oral absorption
Pharmacokinetics Chapter 4.
Boyce/DiPrima 9 th ed, Ch 3.1: 2 nd Order Linear Homogeneous Equations-Constant Coefficients Elementary Differential Equations and Boundary Value Problems,
Pharmacologic Principles Chapter 1, 2, 3. Understanding Nurses must understand both + and – effects of drugs Pharmacotherapeutics –u–use of drugs and.
Laplace transformation
Week 4 - Biopharmaceutics and Pharmacokinetics
Objectives Describe the main physiological changes that occur with aging Identify factors affecting absorption and distribution with the geriatric client.
Gokaraju Rangaraju College of Pharmacy
INTRAVENOUS INFUSION.
VM 8314 Dr. Jeff Wilcke Pharmacokinetic Modeling (describing what happens)
CLEARANCE CONCEPTS Text: Applied Biopharm. & PK
Pharmacokinetics Introduction
10/13/20151Prof. Mazen Qato. OBJECTIVES 10/13/2015Prof. Mazen Qato2.
© Nuffield Foundation 2011 Nuffield Mathematics Activity Drug clearance.
Louisiana Tech University Ruston, LA Slide 1 Compartmental Models Juan M. Lopez BIEN 501 Friday, May 09, 2008.
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation. Fundamentals of Pharmacology for Veterinary Technicians Chapter 3 Therapeutic Range.
Bioavailability Dr Mohammad Issa.
PLASMA HALF LIFE ( t 1/2 ).  Minimum Effective Concentration (MEC): The plasma drug concentration below which a patient’s response is too small for clinical.
PHARMACOKINETICS CH. 4 Part 2. GETTING IN ABSORPTION Definition – the movement of a drug from the site of administration into the fluids of the body.
T(1) = 15 0 CT(2) = 25 0 C A sphere of radius 1 m has a temperature of 15 C and lies inside a sphere of radius 2 m which has a temperature of 25 C. The.
 all drugs not in gaseous state need to use fluid routes of excretion ◦ fluid routes include -sweat, tears, saliva, mucous, urine, bile, human milk ◦
PHARMACOKINETIC MODELS
Pharmacokinetics of Drug Absorption Prepared by: KAZI RASHIDUL AZAM.
Modeling with a Differential Equation
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
1 Some Deterministic Models in Mathematical Biology: Physiologically Based Pharmacokinetic Models for Toxic Chemicals Cammey E. Cole Meredith College January.
CHAPTER 7 ABSORPTION KINETICS.
Continuous intravenous infusion (one-compartment model)
BIOPHARMACEUTICS.
Pharmacokinetics of Drug Absorption Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University.
Drugs and Our Society The Physiological Impact of Drugs Part 5.
Copyright ©2008 by Pearson Education, Inc. Upper Saddle River, New Jersey All rights reserved. Focus on Pharmacology, First Edition By Jahangir Moini.
Design of Sustained Release Dosage Forms
Time Plasma Conc (hr) (mg/L) Below limit of detection 1 Compartment IV Analysis & Renal Elimination 500 mg of tobramycin.
Objectives Compartment Modeling of Drugs Models describing drug concentration-time profiles Multi-compartment Models.
415 PHT Plasma Level – Time Curve
Announcements Topics: -roughly sections 2.3, 3.1, 3.2, and 3.3 * Read these sections and study solved examples in your textbook! Work On: -Practice problems.
Intrinsic Clearance Arthur G. Roberts. Hydrophobic vs. Hydrophilic more bound to plasma proteins more distributed throughout body more metabolized.
Pharmacokinetics 3rd Lecture
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
MULTIPLE DOSAGE REGIMEN
Drug Response Relationships
Compartmental Models and Volume of Distribution
Chapter 8 BIOAVAILABILITY & BIOEQUIVALENCE
Announcements Topics: Work On:
Applications of Pharmacokinetics
Controlled drug release
Gretchen A. Koch Goucher College BioQUEST Summer 2007
Clinical Pharmacokinetics
Selected Bioavailability and Pharmacokinetic Calculations
1 Concentration-time curve
Therapeutic Drug Monitoring chapter 1 part 1
Clinical Pharmacokinetics
Project #1: Drug Kinetics in Genetically Modified Mice
Nuffield Free-Standing Mathematics Activity Drug clearance
Presentation transcript:

Cold Pills & Compartmental Modeling Ronnie Schumann MA 354- Math Modeling Dr. Jyoti Champanerkar Monday, Dec. 5, 2005

Background Idea: Treat body as a set of homogenous compartments through which medication must pass: GI Tract, Bloodstream, Organs, Excretory System. Medication moves from compartment A to compartment B at a rate proportional to amount of drug in compartment A. Important to know: WHERE? WHEN? HOW MUCH? Sensitivity to One Dose vs. Continuous Doses

One Dose: Models x[t]: drug amount in GI at time t y[t]: drug amount in bloodstream at time t k 1 & k 2 : clearance coefficients of GI & bloodstream Assume medication dissolves instantly upon entering body dx(t) dt = -k 1 x(t), x(0) = A dy(t) dt = k 1 x(t) - k 2 y(t), y(0) = 0

One Dose: Models Provided k 1, k 2 > 0 & k 1 ≠ k2 As t  ∞, x[t]  0, y[t]  0: drug is eliminated from system k 1 & k 2 depend on type of drug, specific compartments, age & health of patient x(t) = Ae -k 1 t y(t) = k 1 A k 1 - k 2 (e -k 2 t – e -k 1 t )

Antihistamine in Bloodstream (y[t]) vs. Time (t) Max: y[23.78 hr] =.57 units k 2 =.0231 hr -1 k 1 = hr -1 A = 1 Period: 24 hr

Antihistamine in Bloodstream (y[t]) vs. Time (t) Max: y[17.96 hr] =.66 units k 2 =.0231 hr -1 k 1 =.11 hr -1 A = 1 Period: 24 hr

Antihistamine in Bloodstream (y[t]) vs. Time (t) Max: y[9.26 hr] =.807 units k 2 =.0231 hr -1 k 1 =.3 hr -1 A = 1 Period: 24 hr

Antihistamine in Bloodstream (y[t]) vs. Time (t) Max: y[5.08 hr] =.889 units k 2 =.0231 hr -1 k 1 =.6931 hr -1 A = 1 Period: 24 hr

Antihistamine in Bloodstream (y[t]) vs. Time (t) Max: y[3.86 hr] =.915 units k 2 =.0231 hr -1 k 1 = 1.0 hr -1 A = 1 Period: 24 hr

Antihistamine in Bloodstream (y[t]) vs. Time (t) Max: y[2.83 hr] =.937 units k 2 =.0231 hr -1 k 1 = 1.5 hr -1 A = 1 Period: 24 hr

One Dose: Variance in k 1 Larger k 1 values  higher & quicker peaks in y[t] TRAFFIC JAM!!!

Restrictions Effective range of a drug Fast-acting Long-lasting Effective range: 0.2 – 0.8 units 1. y[t] ≤ 0.8 units, for all t units ≤ y[2 hr] ≤ 0.8 units units ≤ y[24 hr] ≤ 0.8 units Pronounce k 1 values desirable or undesirable

Graphical Examination: Box Plots

Antihistamine in Bloodstream (y[t]) vs. Time (t) units0.577 units y[2 hr] = units; y[24 hr] = units Undesirable Undesirable k 2 =.0231 hr -1 k 1 = hr -1 A = 1 Period: 24 hr

Antihistamine in Bloodstream (y[t]) vs. Time (t) units0.637 units y[2 hr] = units; y[24 hr] = units Undesirable Undesirable k 2 =.0231 hr -1 k 1 =.11 hr -1 A = 1 Period: 24 hr

Antihistamine in Bloodstream (y[t]) vs. Time (t) 0.44 units0.622 units y[2 hr] = 0.44 units; y[24 hr] = units Undesirable  Maximum > 0.8 Undesirable  Maximum > 0.8 k 2 =.0231 hr -1 k 1 =.3 hr -1 A =1 Period: 24 hr

Antihistamine in Bloodstream (y[t]) vs. Time (t) units0.594 units y[2 hr] = units; y[24 hr] = units Undesirable  Maximum > 0.8 Undesirable  Maximum > 0.8 k 2 =.0231 hr -1 k 1 =.6931 hr -1 A = 1 Period: 24 hr

Antihistamine in Bloodstream (y[t]) vs. Time (t) units0.588 units y[2 hr] = units; y[24 hr] = units Undesirable Undesirable k 2 =.0231 hr -1 k 1 = 1.0 hr -1 A = 1 Period: 24 hr

Antihistamine in Bloodstream (y[t]) vs. Time (t) units0.583 units y[2 hr] = units; y[24 hr] = units Undesirable Undesirable k 2 =.0231 hr -1 k 1 = 1.5 hr -1 A = 1 Period: 24 hr

Range of Effective k 1 for k 2 =.0231 Upper Bound: k 1 =.282 Lower Bound: k 1 =.115 Want to maximize range of k 1 for which drug is safe & effective. Small k 1 range: Reformulation Different drug Different concentration Different path Limit Users

Continuous Doses: Model x[t]: drug amount in GI at time t y[t]: drug amount in bloodstream at time t k 1 & k 2 : clearance coefficients of GI & bloodstream R measured in (units / hr) Assume medication dissolves instantly upon entering body dx(t) dt = R - k 1 x(t), x(0) = 0 dy(t) dt = k 1 x(t) - k 2 y(t), y(0) = 0

Continuous Doses: Model Provided k 1, k 2 > 0 & k 1 ≠ k2 As t  ∞, x[t]  (R/k 1 ), y[t]  (R/k 2 ): equilibrium levels k 1 & k 2 depend on type of drug, specific compartments, age & health of patient k 1 & k 2 used for decongestant & antihistamine scenarios x(t) = (1-e -k 1 t ) y(t) = Rk2Rk2 (e -k 2 t – e -k 1 t )] R k 1 1 k 1 – k 2 [1+

Clearance Coefficients & Equilibrium Levels for Young & Healthy DecongestantAntihistamine K 1 (GI) hr -1 Eq: units hr -1 Eq: units K 2 (blood) hr -1 Eq: units hr -1 Eq: units

Clearance Coefficients & Equilibrium Levels for Old & Infirm DecongestantAntihistamine K 1 (GI) hr -1 Eq: units hr -1 Eq: units K 2 (blood) hr -1 Eq: units hr -1 Eq: units

Young’uns vs. Elders: GI/decongestant Equilibrium:.7215 units 30 hours

Young’uns vs. Elders: Blood/decongestant Equilibrium: units 30 hours

Young’uns vs. Elders: GI/decongestant Equilibrium: units 30 hours

Young’uns vs. Elders: Blood/decongestant Equilibrium: units 72 hours (3 days)

Young’uns vs. Elders: GI/antihistamine Equilibrium: units 30 hours

Young’uns vs. Elders: Blood/antihistamine Equilibrium: units 120 hours (5 days)

Young’uns vs. Elders: GI/antihistamine Equilibrium: units 30 hours

Young’uns vs. Elders: Blood/antihistamine Equilibrium: units 336 hours (14 days)

Restrictions: Elderly Blood/antihistamine Effective range of a drug Fast-acting Long-lasting Effective range: units 1. y[t] ≤ 50 units, for all t units ≤ y[24 hr] ≤ 50 units units ≤ y[120 hr] ≤ 50 units

Elders: Blood/antihistamine Function increases too rapidly between 24 hours & 120 hours k 1 =. 231 hr -1 k 2 =.0077 hr -1 R = 1 unit/hr y[24] = units y[120] = units

Elders: Blood/antihistamine Function increases too rapidly between 24 hours & 120 hours k 1 =. 231 hr -1 k 2 =.0077 hr -1 R = 1.4 unit/hr

Elders: Blood/antihistamine Function increases too rapidly between 24 hours & 120 hours k 1 =. 231 hr -1 k 2 =.0077 hr -1 R =.65 unit/hr

Elders: Blood/antihistamine No constant continuous dosage amount satisfies both conditions Solution: Discontinuous dosage Vary treatment times Vary treatment amounts

Applications & Drawbacks Cannot track movement AND absorption of drugs at one time—can devise set of related systems to describe nearly all attributes of drug flow. Versatile technique for absorption modeling. Complex compartmental models useful in epidemiology when several possible paths are present.

Bibliography Borrelli, Robert L. & Courtney S. Coleman. Differential Equations: A Modeling Perspective. Preliminary ed. New York: John Wiley & Sons, Inc., Foster, David. Principles of Clinical Pharmacology. University of Washington. Undated. slides_ ppt#1. slides_ ppt#1 Giordano, Frank, M. Weir, & W. Fox. A First Course in Mathematical Modeling. 3 rd ed. Pacific Grove, CA: Brooks/Cole- Thomson Learning, White, Emma. Epidemic Models for Drug Use. NUI Maynooth. Undated. IHRCConferenceMarch2005-Emma.pdf. IHRCConferenceMarch2005-Emma.pdf QUESTIONS ?